Ion Channels as Therapeutic Targets: A Drug Discovery Perspective

被引:234
作者
Bagal, Sharan [1 ]
Brown, Alan D. [1 ]
Cox, Peter J. [2 ]
Omoto, Kiyoyuki [1 ]
Owen, Robert M. [1 ]
Pryde, David C. [1 ]
Sidders, Benjamin [2 ]
Skerratt, Sarah E. [1 ]
Stevens, Edward B. [2 ]
Storer, R. Ian [1 ]
Swain, Nigel A. [1 ]
机构
[1] Pfizer Neusentis, Worldwide Med Chem, Cambridge CB21 6GS, England
[2] Pfizer Neusentis, Cambridge CB21 6GS, England
关键词
GATED SODIUM-CHANNELS; NICOTINIC ACETYLCHOLINE-RECEPTORS; IONOTROPIC GLUTAMATE RECEPTORS; OF-FUNCTION MUTATIONS; POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; NEUROPATHIC PAIN; BINDING-SITE; K+ CHANNELS; P2X(7) RECEPTOR;
D O I
10.1021/jm3011433
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ion channels are membrane proteins expressed in almost all living cells. The sequencing of the human genome has identified more than 400 putative ion channels, but only a fraction of these have been cloned and functionally tested. The widespread tissue distribution of ion channels, coupled with the plethora of physiological consequences of their opening and closing, makes ion-channel-targeted drug discovery highly compelling. However, despite some important drugs in clinical use today, as a class, ion channels remain underexploited in drug discovery and many existing drugs are poorly selective with significant toxicities or suboptimal efficacy. This Perspective seeks to review the ion channel family, its structural and functional features, and the diseases that are known to be modulated by members of the family. In particular, we will explore the structure and properties of known ligands and consider the future prospects for drug discovery in this challenging but high potential area.
引用
收藏
页码:593 / 624
页数:32
相关论文
共 243 条
[1]  
[Anonymous], 2011, MED LETT DRUGS THER, V53, P94
[2]  
[Anonymous], RES DEV
[3]   Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors [J].
Arias, HR .
NEUROCHEMISTRY INTERNATIONAL, 2000, 36 (07) :595-645
[4]   Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors [J].
Arias, Hugo R. ;
Bhumireddy, Pankaj ;
Bouzat, Cecilia .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (08) :1254-1276
[5]   From molecule to malady [J].
Ashcroft, FM .
NATURE, 2006, 440 (7083) :440-447
[6]  
Atack JR, 2011, CURR TOP MED CHEM, V11, P1176
[7]   TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for α2-and α3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates [J].
Atack, JR ;
Wafford, KA ;
Tye, SJ ;
Cook, SM ;
Sohal, B ;
Pike, A ;
Sur, C ;
Melillo, D ;
Bristow, L ;
Bromidge, F ;
Ragan, I ;
Kerby, J ;
Street, L ;
Carling, R ;
Castro, JL ;
Whiting, P ;
Dawson, GR ;
McKernan, RM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (01) :410-422
[8]   The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics [J].
Atack, JR .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (05) :601-618
[9]   Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia [J].
Ataga, Kenneth I. ;
Smith, Wally R. ;
De Castro, Laura M. ;
Swerdlow, Paul ;
Saunthararajah, Yogen ;
Castro, Oswaldo ;
Vichinsky, Elliot ;
Kutlar, Abdullah ;
Orringer, Eugene P. ;
Rigdon, Greg C. ;
Stocker, Jonathan W. .
BLOOD, 2008, 111 (08) :3991-3997
[10]  
Aurell C. J., 2012, Patent No. [WO2012039657, 2012039657]